These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9441469)

  • 1. [Diagnosis and treatment of severe hyperlipidemia].
    Tonstad S; Leren TP; Ose L
    Tidsskr Nor Laegeforen; 1997 Nov; 117(29):4241-4. PubMed ID: 9441469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dyslipidemia - when are lipid lowering medications useful in clinical practice?].
    Blum MR; Stanga Z; Rodondi N
    Praxis (Bern 1994); 2013 May; 102(10):585-9. PubMed ID: 23644243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
    D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
    Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    Yamamoto A; Yamamura T; Yokoyama S; Sudo H; Matsuzawa Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):493-7. PubMed ID: 6500769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe familial hypercholesterolaemia: current and future management.
    Farnier M; Bruckert E
    Arch Cardiovasc Dis; 2012 Dec; 105(12):656-65. PubMed ID: 23199621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
    J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs.
    Wu NQ; Guo YL; Xu RX; Liu J; Zhu CG; Jiang LX; Li JJ
    Clin Lab; 2013; 59(7-8):901-7. PubMed ID: 24133922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
    Clauss S; Wai KM; Kavey RE; Kuehl K
    J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
    Molcányiová A; Stancáková A; Javorský M; Tkác I
    Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
    Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
    Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolemia in children and adolescents.
    McCrindle BW
    Curr Opin Lipidol; 2012 Dec; 23(6):525-31. PubMed ID: 22914663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial hypercholesterolaemia.
    Nair DR; Sharifi M; Al-Rasadi K
    Curr Opin Cardiol; 2014 Jul; 29(4):381-8. PubMed ID: 24870549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment.
    Santos PC; Pereira AC
    Pharmacogenomics; 2015; 16(15):1743-50. PubMed ID: 26427613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary hyperlipoproteinemias--pathophysiology, clinical aspects and genetics].
    Keller C; Zöllner N
    Internist (Berl); 1992 Jan; 33(1):9-15. PubMed ID: 1551767
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing homozygous familial hypercholesterolaemia from cradle to grave.
    Thompson GR
    Atheroscler Suppl; 2015 May; 18():16-20. PubMed ID: 25936299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
    Geiss HC; Schwandt P; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2002 Jun; 110(4):182-7. PubMed ID: 12058342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.